Great Strides Made in Strategic Priorities, with Underlying EBITDA up 20%
Clinigen Group plc (AIM: CLIN, 'Clinigen', or the 'Group'), the global specialty pharmaceuticals business, has today published its full year results for the 12 months ended 30 June 2015.
The Group has also announced today a proposed acquisition of Link Healthcare ('Link') to strengthen Clinigen's global footprint in Asia, Africa and Australasia, for an initial consideration of £44.5m (rising to a maximum of £100m if performance milestones over two years are achieved) - see separate release.
Financial highlights
- Revenues increased by 45% to £184.4m (2014: £126.6m)
- Gross profit increased 30%, mainly driven by 25% growth in Clinigen Specialty Pharmaceuticals (SP) gross profits and the acquisition of Idis Group Holdings Limited ('Idis') in April 2015
- Underlying EBITDA up 20% to £32.3m (2014: £26.8m)
- Adjusted underlying earnings per share up 14% to 28.0 pence (2014: 24.5 pence), reported earnings per share at 6.0 pence (2014: 19.6 pence) are after one off acquisition costs and post-acquisition restructuring cost
- Final dividend 2.3 pence per share proposed; total dividend 3.4 pence per share (2014: 3.1 pence per share), up 10%
